 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Dymelor |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a602021 |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 90% |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.012.301 |
| Chemical and physical data | |
| Formula | C15H20N2O4S |
| Molar mass | 324.40 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 188 to 190 °C (370 to 374 °F) |
| |
| |
| (verify) | |
Acetohexamide (trade nameDymelor) is a first-generationsulfonylureamedication used to treatdiabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone.[1]
Acetohexamide binds to anATP-sensitive K+ (KATP) channel on the cell membrane ofpancreatic beta cells. This inhibits the outflux ofpotassium, which causes themembrane potential to become more positive. This depolarization in turn opensvoltage-gated calcium channels. The rise in intracellularcalcium leads to increased fusion ofinsulin granulae with the cell membrane, and therefore increased secretion of insulin.[2]
Sulfonylureas, especially first-generation sulfonylureas such as Acetohexamide, can cause severe hypoglycemia and increase the risk of adverse cardiovascular events.[3][4]
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |
